broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K62627508-001-01-5 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 0.743301 | 0.09614 | 0.038569 | 0.869374 | 0.053642 | null | idasanutlin | MDM inhibitor | MDM2, TP53 | null | null | COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O | Phase 3 | true | ACH-000900 |
BRD-K63504947-001-14-7 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 1.033799 | -0.883422 | -0.026203 | 1 | 0.494221 | null | semaxanib | VEGFR inhibitor | FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET | null | null | Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1 | Phase 3 | true | ACH-000900 |
BRD-K63712959-001-01-8 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 0.921931 | 0.082678 | -0.046128 | 0.966882 | 3.301996 | null | temoporfin | radical formation stimulant | null | oncology | head and neck squamous cell carcinoma (HNSCC) | Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2 | Launched | true | ACH-000900 |
BRD-K64052750-001-22-5 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 0.81036 | -7.970512 | -0.005937 | 0.878984 | 0.298445 | null | gefitinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1 | Launched | true | ACH-000900 |
BRD-K64881305-001-03-7 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 0.067786 | 9.411326 | 0.846647 | 0.446968 | 0.031598 | 0.032091 | ispinesib | kinesin inhibitor | KIF11 | null | null | CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1 | Phase 2 | true | ACH-000900 |
BRD-K66175015-001-12-4 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 0.157264 | 2.899949 | 0.516168 | 0.863512 | 2.084383 | 2.374289 | afatinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | oncology | non-small cell lung cancer (NSCLC) | CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1 | Launched | true | ACH-000900 |
BRD-K67844266-003-01-9 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 0.526731 | 4.487752 | 0.473244 | 0.892226 | 1.097066 | null | pevonedistat | nedd activating enzyme inhibitor | NAE1, UBA3 | null | null | NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12 | Phase 2 | true | ACH-000900 |
BRD-K69001009-001-02-8 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 0.866081 | -0.230979 | 0.076288 | 0.911486 | 1.8694 | null | golvatinib | VEGFR inhibitor | KDR, MET | null | null | CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1 | Phase 2 | true | ACH-000900 |
BRD-K69694239-001-02-2 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 0.228945 | 4.198002 | 0.730404 | 0.661529 | 0.141214 | 0.163388 | bardoxolone-methyl | nuclear factor erythroid derived, like (NRF2) activator | PPARG, STAT3 | null | null | COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 | Phase 3 | true | ACH-000900 |
BRD-K69776681-001-03-8 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 0.053251 | 0.585526 | 0.585234 | 0.429497 | 0.02529 | 0.030653 | volasertib | PLK inhibitor | PLK1 | null | null | CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O | Phase 3 | true | ACH-000900 |
BRD-K70301465-001-05-9 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 0.976413 | 0.290835 | -0.074008 | 0.987653 | 0.053706 | null | ibrutinib | Bruton's tyrosine kinase (BTK) inhibitor | BLK, BMX, BTK | hematologic malignancy | chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM) | Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C | Launched | true | ACH-000900 |
BRD-K70401845-001-15-7 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 1.352284 | 0.946887 | 0.395935 | 1 | 0.776896 | null | erlotinib | EGFR inhibitor | EGFR, NR1I2 | oncology | non-small cell lung cancer (NSCLC), pancreatic cancer | COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC | Launched | true | ACH-000900 |
BRD-K73838513-003-05-5 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 0.417643 | 1.04533 | 0.698784 | 0.894632 | 2.039544 | null | cinacalcet | calcium channel activator | CASR | endocrinology, nephrology, oncology | hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia | C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12 | Launched | true | ACH-000900 |
BRD-K74514084-003-09-2 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 1.132797 | -0.082591 | -0.097247 | 1 | 1,127.196901 | null | pazopanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3 | oncology | renal cell carcinoma (RCC), soft tissue sarcoma (STS) | CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1 | Launched | true | ACH-000900 |
BRD-K75009076-001-02-1 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 0.29266 | 1.837266 | 0.719088 | 0.783648 | 0.51509 | 0.831682 | SCH-900776 | CHK inhibitor | CDK2, CHEK1 | null | null | Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1 | Phase 2 | true | ACH-000900 |
BRD-K76210423-001-01-6 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 0.904444 | 2.331359 | 0.126224 | 0.973472 | 0.676501 | null | resiquimod | toll-like receptor agonist | TLR7, TLR8 | null | null | CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O | Phase 3 | true | ACH-000900 |
BRD-K76239644-001-02-6 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 0.847257 | -2.261245 | 0.138532 | 0.91653 | 0.122616 | null | BMS-690514 | EGFR inhibitor, VEGFR inhibitor | EGFR, ERBB2, FLT3, KDR | null | null | COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1 | Phase 2 | true | ACH-000900 |
BRD-K76674262-001-03-3 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 0.10165 | 1.657441 | 0.661535 | 0.653009 | 0.235821 | 0.270474 | homoharringtonine | protein synthesis inhibitor | RPL3 | hematologic malignancy | chronic myeloid leukemia (CML) | COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC | Launched | true | ACH-000900 |
BRD-K76908866-001-07-6 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 0.910228 | -0.056583 | -0.170046 | 0.949858 | 5.125415 | null | CP-724714 | EGFR inhibitor, protein tyrosine kinase inhibitor | ERBB2 | null | null | COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1 | Phase 2 | true | ACH-000900 |
BRD-K77625799-001-07-7 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 0.754024 | -1.319502 | 0.230181 | 0.908764 | 0.022175 | null | vandetanib | EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA | oncology | medullary thyroid cancer (MTC) | COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1 | Launched | true | ACH-000900 |
BRD-K78431006-001-15-1 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 0.364183 | 0.104353 | 0.164463 | 0.725807 | 1.171904 | null | crizotinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl | Launched | true | ACH-000900 |
BRD-K79254416-001-21-8 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 0.064351 | 0.634866 | 0.72245 | 0.572739 | 0.123943 | 0.153981 | decitabine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML) | Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1 | Launched | true | ACH-000900 |
BRD-K81016934-001-02-0 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 0.910347 | 0.138155 | -0.010038 | 0.949563 | 0.011815 | null | INC-280 | c-Met inhibitor | MET | null | null | CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1 | Phase 2 | true | ACH-000900 |
BRD-K81418486-001-44-2 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 0.75284 | 0.016882 | 0.002062 | 0.876504 | 0.084614 | null | vorinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9 | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1 | Launched | true | ACH-000900 |
BRD-K81473043-001-19-5 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 0.131234 | 4.849658 | 0.885903 | 0.770938 | 0.048367 | 0.051501 | tanespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 3 | true | ACH-000900 |
BRD-K82135108-001-04-3 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 0.351333 | 3.885047 | 0.51746 | 0.665262 | 0.066845 | 0.091338 | elesclomol | oxidative stress inducer | HSPA1A | null | null | CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1 | Phase 3 | true | ACH-000900 |
BRD-K82818427-001-04-8 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 0.690958 | 3.106122 | 0.307055 | 0.828693 | 0.046104 | null | batimastat | matrix metalloprotease inhibitor | ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8 | null | null | CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO | Phase 3 | true | ACH-000900 |
BRD-K83029223-001-01-3 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 0.110223 | 4.567891 | 0.867912 | 0.574933 | 0.006058 | 0.006397 | litronesib | kinesin-like spindle protein inhibitor | KIF11 | null | null | CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 | Phase 2 | true | ACH-000900 |
BRD-K83988098-001-02-0 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 0.119482 | 1.020398 | 0.619796 | 0.722941 | 0.007689 | 0.010048 | alvespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 2 | true | ACH-000900 |
BRD-K85402309-043-01-9 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 0.223632 | 1.965308 | 0.49716 | 0.936306 | 1.474184 | 1.993276 | dovitinib | EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB | null | null | CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O | Phase 3 | true | ACH-000900 |
BRD-K85606544-001-09-1 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 0.833251 | -3.443876 | -0.116162 | 0.898854 | 0.219711 | null | neratinib | EGFR inhibitor | EGFR, ERBB2, KDR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 3 | true | ACH-000900 |
BRD-K86118762-001-01-8 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 0.736834 | 0.3489 | 0.115508 | 0.861176 | 0.052999 | null | linsitinib | IGF-1 inhibitor | IGF1R, INSR, INSRR | null | null | C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 | Phase 3 | true | ACH-000900 |
BRD-K86972824-001-01-4 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 0.619033 | 2.5421 | 0.195011 | 0.958236 | 3.546411 | null | oltipraz | nuclear factor erythroid derived, like (NRF2) activator | ANG | null | null | Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1 | Phase 3 | true | ACH-000900 |
BRD-K87737963-001-06-0 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 0.853025 | 2.445471 | 0.268252 | 0.986352 | 4.259773 | null | cyt387 | null | JAK1, JAK2, JAK3 | null | null | O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1 | Phase 3 | true | ACH-000900 |
BRD-K87782578-001-01-4 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 0.275887 | 0.74537 | 0.091616 | 0.857385 | 2.13067 | 6.252781 | AVL-292 | Bruton's tyrosine kinase (BTK) inhibitor | BTK, YES1 | null | null | COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1 | Phase 2 | true | ACH-000900 |
BRD-K87909389-003-03-4 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 0.171535 | 1.289587 | 0.784705 | 0.603982 | 0.096758 | 0.134028 | alvocidib | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM | null | null | CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000900 |
BRD-K88510285-001-17-8 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 0.156025 | 7.495973 | 0.558843 | 0.547604 | 0.013788 | 0.014494 | bortezomib | NFkB pathway inhibitor, proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA | hematologic malignancy | multiple myeloma, mantle cell lymphoma (MCL) | CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O | Launched | true | ACH-000900 |
BRD-K89014967-001-04-3 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | -2.511569 | 4.332393 | 0.455343 | 0.985866 | 14.773509 | 9.760801 | AS-703026 | MEK inhibitor | MAP2K1, MAP2K2 | null | null | OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F | Phase 2 | true | ACH-000900 |
BRD-K92441787-001-04-1 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 0.907119 | -0.949077 | -0.004183 | 0.936862 | 0.472139 | null | bexarotene | retinoid receptor agonist | RXRA, RXRB, RXRG | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C | Launched | true | ACH-000900 |
BRD-K95142244-001-01-5 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 0.43886 | 1.197046 | 0.609557 | 0.647081 | 0.022111 | 0.127941 | talazoparib | PARP inhibitor | PARP2 | null | null | Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1 | Phase 3 | true | ACH-000900 |
BRD-K96123349-236-02-8 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 0.719657 | 0.161669 | -0.03584 | 0.824908 | 0.002868 | null | brequinar | dihydroorotate dehydrogenase inhibitor | DHODH | null | null | Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F | Phase 2 | true | ACH-000900 |
BRD-K98572433-001-02-9 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 1.367952 | 0.298085 | 0.021421 | 1 | 2.74151 | null | AZD8931 | EGFR inhibitor | EGFR, ERBB2, ERBB3 | null | null | CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC | Phase 2 | true | ACH-000900 |
BRD-K99113996-001-02-0 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 0.782678 | 2.520238 | 0.265208 | 0.895722 | 0.094985 | null | AZD2014 | mTOR inhibitor | MTOR | null | null | CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C | Phase 2 | true | ACH-000900 |
BRD-K99616396-001-05-1 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 0.901853 | 1.264906 | -0.042166 | 0.961987 | 0.234652 | null | motesanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT1, FLT4, KDR, KIT | null | null | CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12 | Phase 3 | true | ACH-000900 |
BRD-K99749624-001-07-0 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 1.267774 | -1.885175 | 0.059809 | 1 | 0.211939 | null | linifanib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK | null | null | Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1 | Phase 3 | true | ACH-000900 |
BRD-M97302542-001-04-4 | ACH-000900 | NCIH23_LUNG | MTS010 | 1 | 0.923287 | 0.129867 | -0.096935 | 0.944922 | 0.000047 | null | dichloroacetate | pyruvate dehydrogenase kinase inhibitor | PDK1 | null | null | [Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl | Phase 3 | true | ACH-000900 |
BRD-A25234499-001-19-1 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 0.92508 | -1.10741 | 0.056284 | 0.967927 | 0.038593 | null | aminoglutethimide | glucocorticoid receptor antagonist | CYP11A1, CYP19A1 | endocrinology, oncology | Cushing's syndrome, breast cancer | CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1 | Launched | true | ACH-000901 |
BRD-A70858459-001-01-7 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 1.072834 | -0.060141 | -0.022201 | 1 | 0.043937 | null | estramustine | DNA alkylating agent | ESR1, ESR2, MAP1A, MAP2 | oncology | prostate cancer | C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O | Launched | true | ACH-000901 |
BRD-A74914197-001-02-9 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 1.682099 | 0.395738 | 0.322025 | 1 | 0.116122 | null | pralatrexate | dihydrofolate reductase inhibitor | DHFR, TYMS | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 | Launched | true | ACH-000901 |
BRD-K02113016-001-19-6 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 2.195546 | 2.307634 | 0.018919 | 1 | 23.537432 | null | olaparib | PARP inhibitor | PARP1, PARP2 | oncology | ovarian cancer | Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1 | Launched | true | ACH-000901 |
BRD-K02130563-001-11-4 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 0.120366 | 6.382734 | 0.768513 | 0.718869 | 0.449773 | 0.469602 | panobinostat | HDAC inhibitor | HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | multiple myeloma | Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1 | Launched | true | ACH-000901 |
BRD-K03390685-001-01-7 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 0.768079 | 0.35654 | -0.052838 | 0.933377 | 1.754588 | null | cobimetinib | MEK inhibitor | null | oncology | melanoma | OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1 | Launched | true | ACH-000901 |
BRD-K03406345-001-21-1 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 1.146648 | 0.334838 | 0.07975 | 1 | 0.262895 | null | azacitidine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL) | Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000901 |
BRD-K03449891-001-08-6 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | -0.134053 | 3.901096 | 0.474464 | 0.952818 | 7.087075 | 6.66844 | foretinib | VEGFR inhibitor | FLT1, FLT4, KDR, MET | null | null | COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1 | Phase 2 | true | ACH-000901 |
BRD-K03765900-001-01-9 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 1.546664 | 1.593858 | 0.051822 | 1 | 0.124138 | null | XL-647 | EGFR inhibitor, VEGFR inhibitor | EGFR, EPHB4, ERBB2, FLT4, KDR | null | null | COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1 | Phase 3 | true | ACH-000901 |
BRD-K05804044-001-18-5 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 2.652447 | 0.760022 | 0.4076 | 1 | 10.366647 | null | AZ-628 | RAF inhibitor | BRAF, RAF1 | null | null | Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1 | Preclinical | true | ACH-000901 |
BRD-K06814349-304-02-7 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 0.113822 | 10.162642 | 0.775893 | 0.852233 | 1.982525 | 2.033551 | fosbretabulin | tubulin polymerization inhibitor, VE-cadherin antagonist | CDH5 | null | null | COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O | Phase 3 | true | ACH-000901 |
BRD-K08109215-001-06-4 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 2.098715 | 0.738395 | 0.678397 | 1 | 0.924295 | null | I-BET-762 | bromodomain inhibitor | BRD2, BRD3, BRD4 | null | null | CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 | Phase 2 | true | ACH-000901 |
BRD-K08542803-001-02-3 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 0.047645 | 0.849834 | 0.605067 | 0.698745 | 0.505878 | 0.569143 | gambogic-acid | caspase activator | BCL2 | null | null | CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C | Phase 2 | true | ACH-000901 |
BRD-K08547377-001-04-4 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 0.20461 | 0.878527 | 0.675175 | 0.582703 | 0.061067 | 0.111169 | irinotecan | topoisomerase inhibitor | TOP1, TOP1MT | oncology | colorectal cancer | CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12 | Launched | true | ACH-000901 |
BRD-K08703257-001-13-9 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 1.611396 | 0.836325 | 0.064048 | 1 | 7.895389 | null | 3-amino-benzamide | PARP inhibitor | PARP1 | null | null | NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1 | Phase 2 | true | ACH-000901 |
BRD-K08799216-001-05-3 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 1.256053 | 0.136649 | -0.009489 | 1 | 0.109955 | null | pelitinib | EGFR inhibitor | EGFR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 2 | true | ACH-000901 |
BRD-K09951645-001-11-8 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 1.228066 | 3.592386 | 0.103679 | 1 | 0.0273 | null | dabrafenib | RAF inhibitor | BRAF, LIMK1, NEK11, RAF1, SIK1 | oncology | melanoma | CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F | Launched | true | ACH-000901 |
BRD-K11267252-001-05-1 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 0.833078 | 6.028176 | -0.004191 | 0.893024 | 0.019903 | null | alectinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1 | Launched | true | ACH-000901 |
BRD-K11630072-001-13-2 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 1.023267 | -0.066667 | -0.009262 | 1 | 57.147207 | null | carmofur | thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O | Launched | true | ACH-000901 |
BRD-K12184916-001-19-6 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 0.785928 | 3.593964 | 0.169741 | 0.869094 | 0.025768 | null | NVP-BEZ235 | mTOR inhibitor, PI3K inhibitor | ATR, MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1 | Phase 2 | true | ACH-000901 |
BRD-K12343256-001-14-7 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 0.896947 | -0.310216 | 0.018386 | 0.973275 | 0.001513 | null | trametinib | MEK inhibitor | MAP2K1, MAP2K2 | oncology | melanoma | CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O | Launched | true | ACH-000901 |
BRD-K13049116-001-04-0 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 1.329492 | 0.126979 | -0.009603 | 1 | 156.609108 | null | BMS-754807 | IGF-1 inhibitor | AKT1, IGF1R | null | null | C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1 | Phase 2 | true | ACH-000901 |
BRD-K13390322-001-06-3 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 0.151425 | 10.690449 | 0.709819 | 0.806133 | 1.089205 | 1.126588 | AT-7519 | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK9 | null | null | Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1 | Phase 2 | true | ACH-000901 |
BRD-K13514097-001-04-6 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 0.883642 | 5.38859 | 0.101569 | 0.925282 | 0.019661 | null | everolimus | mTOR inhibitor | MTOR | oncology, neurology/psychiatry, genetics, urology | breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO | Launched | true | ACH-000901 |
BRD-K13662825-001-07-5 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 0.136473 | 7.497788 | 0.725406 | 0.61814 | 0.034261 | 0.035749 | dinaciclib | CDK inhibitor | CDK1, CDK2, CDK5, CDK9 | null | null | CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO | Phase 3 | true | ACH-000901 |
BRD-K14109347-001-03-4 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 0.655256 | 0.282053 | 0.011963 | 0.84017 | 0.1416 | null | LY2603618 | CHK inhibitor | CHEK1 | null | null | Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1 | Phase 2 | true | ACH-000901 |
BRD-K15179879-001-03-2 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 0.118162 | 7.345173 | 0.889791 | 0.59946 | 0.121802 | 0.126356 | carfilzomib | proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9 | hematologic malignancy | multiple myeloma | CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1 | Launched | true | ACH-000901 |
BRD-K15600710-066-05-8 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 0.861189 | 0.185566 | -0.018617 | 0.923525 | 0.023688 | null | obatoclax | BCL inhibitor | BCL2 | null | null | COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 | Phase 3 | true | ACH-000901 |
BRD-K16730910-001-10-7 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 1.268471 | -0.129752 | -0.064057 | 1 | 0.020007 | null | regorafenib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK | oncology | colorectal cancer, gastrointestinal stromal tumors (GIST) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1 | Launched | true | ACH-000901 |
BRD-K17555800-003-02-3 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 1.388704 | 1.159995 | 0.199833 | 1 | 0.048982 | null | talmapimod | p38 MAPK inhibitor | MAPK11, MAPK14 | null | null | C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C | Phase 2 | true | ACH-000901 |
BRD-K17610631-001-03-3 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 0.785679 | 5.346351 | 0.114444 | 0.919459 | 0.252521 | null | indisulam | CDK inhibitor | CA1, CA12, CA14, CA2, CA6, CA7, CA9 | null | null | NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12 | Phase 2 | true | ACH-000901 |
BRD-K17743125-001-08-4 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | -0.660491 | 3.192892 | 0.538309 | 0.961308 | 9.823297 | 7.54619 | belinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1 | Launched | true | ACH-000901 |
BRD-K17894950-001-14-3 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 1.671399 | -0.987921 | 0.368187 | 1 | 0.002181 | null | indirubin | CDK inhibitor, glycogen synthase kinase inhibitor | CDK1, CDK5, GSK3A | null | null | O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O | Phase 2/Phase 3 | true | ACH-000901 |
BRD-K18961567-001-01-1 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 0.230162 | 7.928637 | 0.576745 | 0.964347 | 6.402979 | 6.920966 | LY2801653 | MET inhibitor | MET | null | null | Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1 | Phase 2 | true | ACH-000901 |
BRD-K19540840-001-09-4 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 1.447495 | 3.219094 | 0.354376 | 1 | 0.221776 | null | saracatinib | src inhibitor | ABL1, LCK, SRC, YES1 | null | null | CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1 | Phase 2/Phase 3 | true | ACH-000901 |
BRD-K19687926-001-04-1 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 0.951219 | -2.699628 | -0.156382 | 0.970759 | 0.204991 | null | lapatinib | EGFR inhibitor | EGFR, ERBB2 | oncology | breast cancer | CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1 | Launched | true | ACH-000901 |
BRD-K19796430-001-05-6 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 1.177847 | 0.101667 | -0.001292 | 1 | 0.002339 | null | sonidegib | smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1 | Launched | true | ACH-000901 |
BRD-K22064724-001-01-8 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 0.093751 | 4.81478 | 0.788226 | 0.774745 | 0.896215 | 0.93571 | napabucasin | STAT inhibitor | STAT3 | null | null | CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O | Phase 3 | true | ACH-000901 |
BRD-K22822991-001-02-3 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 0.67582 | -0.055345 | -0.016176 | 0.839684 | 0.052468 | null | odanacatib | cathepsin inhibitor | CTSK | null | null | CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N | Phase 3 | true | ACH-000901 |
BRD-K23228615-001-02-8 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 0.881206 | 0.562858 | 0.030685 | 0.936297 | 0.05229 | null | GDC-0980 | mTOR inhibitor, PI3K inhibitor | FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK | null | null | C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1 | Phase 2 | true | ACH-000901 |
BRD-K23984367-001-07-5 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 1.24884 | 0.043245 | -0.018178 | 1 | 0.008489 | null | sorafenib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET | oncology | renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1 | Launched | true | ACH-000901 |
BRD-K28822270-001-03-7 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 2.088235 | 0.132118 | -0.154363 | 1 | 10,387.996377 | null | resminostat | HDAC inhibitor | HDAC1, HDAC3, HDAC6, HDAC8 | null | null | CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO | Phase 2 | true | ACH-000901 |
BRD-K29905972-001-06-3 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 0.556054 | 43.727119 | 0.379338 | 0.924833 | 1.933695 | null | axitinib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, FLT1, FLT4, KDR, PLK4 | oncology | renal cell carcinoma (RCC) | CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1 | Launched | true | ACH-000901 |
BRD-K30577245-001-05-0 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 0.190354 | 1.586776 | 0.585142 | 0.657394 | 0.010296 | 0.013926 | docetaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1 | oncology | breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC) | CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C | Launched | true | ACH-000901 |
BRD-K31698212-001-02-9 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 0.960179 | -0.024317 | 0.000143 | 0.980542 | 0.012006 | null | icotinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1 | Launched | true | ACH-000901 |
BRD-K31928526-001-02-1 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 1.002533 | 0.165937 | -0.000648 | 1 | 0.019476 | null | barasertib | Aurora kinase inhibitor | AURKA, AURKB | null | null | CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O | Phase 2/Phase 3 | true | ACH-000901 |
BRD-K33379087-001-07-5 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 0.901421 | -5.802759 | -0.122005 | 0.950383 | 0.080659 | null | tivantinib | tyrosine kinase inhibitor | MET | null | null | O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23 | Phase 3 | true | ACH-000901 |
BRD-K33610132-001-02-9 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 1.511852 | 0.361718 | 0.152717 | 1 | 0.859119 | null | rociletinib | EGFR inhibitor | EGFR | null | null | COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O | Phase 3 | true | ACH-000901 |
BRD-K35520305-001-16-9 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 0.810126 | 1.559296 | 0.098654 | 0.920174 | 0.169251 | null | dacarbazine | DNA alkylating agent | PGD, POLA2 | oncology, hematologic malignancy | melanoma, Hodgkin's lymphoma | CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O | Launched | true | ACH-000901 |
BRD-K37379014-001-02-0 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 0.446954 | 0.43188 | 0.215984 | 0.751803 | 0.002307 | null | filanesib | kinesin inhibitor, kinesin-like spindle protein inhibitor | KIF11 | null | null | CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F | Phase 3 | true | ACH-000901 |
BRD-K38332599-001-01-3 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 0.754282 | 0.342105 | -0.01839 | 0.852455 | 0.018346 | null | uprosertib | AKT inhibitor | AKT1, AKT2, AKT3 | null | null | Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1 | Phase 2 | true | ACH-000901 |
BRD-K38527262-300-01-0 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 1.021165 | -0.115932 | -0.04203 | 1 | 0.006667 | null | atiprimod | JAK inhibitor, STAT inhibitor | JAK2, STAT3 | null | null | CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1 | Phase 2 | true | ACH-000901 |
BRD-K38852836-001-02-1 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 0.206079 | 1.661635 | 0.693325 | 0.556353 | 0.01105 | 0.015214 | ganetespib | HSP inhibitor | HSP90AA1 | null | null | CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O | Phase 3 | true | ACH-000901 |
BRD-K39974922-001-04-3 | ACH-000901 | HCC1359_LUNG | MTS010 | 1 | 0.909166 | -0.215926 | -0.032181 | 0.94621 | 0.512198 | null | lenvatinib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT4, KDR | oncology | thyroid cancer | COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O | Launched | true | ACH-000901 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.